Search for


TEXT SIZE

search for



CrossRef (0)
Report of the Korean Association of External Quality Assessment Service on Complement and Immunoglobulin (2018)
J Lab Med Qual Assur 2019;41:195-200
Published online December 31, 2019
© 2019 Korean Association of External Quality Assessment Service.

Kyeong-Hee Kim

Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea
Correspondence to: Kyeong-Hee Kim
Department of Laboratory Medicine, Dong-A University Hospital, Dong-A University College of Medicine, 26 Daesingongwon-ro, Seo-gu, Busan 49201, Korea
Tel: +82-51-240-2850 Fax: +82-51-255-9366 E-mail: progreen@dau.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract

In 2018, the complement and immunoglobulin proficiency testing program of the Korean Association of External Quality Assessment Service included complement, free light chain, immunoglobulin, and anti-cyclic citrullinated peptide (anti-CCP). Tests on all nine items were conducted. The specimen used in the complement and immunoglobulin proficiency testing program was Liquichek Immunology Control from Bio-Rad (Bio-Rad Laboratories, USA). In April and October, three quality control specimens were frozen and delivered. The quantitative proficiency testing report included the number of participating organizations in each group, mean, standard deviation, coefficient of variation (CV), median, minimum, and maximum values. The number of organizations participating in each test varied and ranged from 29 free light chains to 115 anti-CCP participants. The median CV of C3 was 4.9%, and the median CV of C4 was 8.45%, which was statistically significantly lower (P=0.013). The median CV for the free light chain κ and the free light chain λ were 7.96 and 6.21, respectively, with a high CV for the free light chain κ, but no statistical difference (P =0.092). The median CV of immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM) were good at 4.5, 4.48, and 3.56, but the median CV of immunoglobulin E was 7.75, which was statistically significantly higher than that of IgA, IgG, and IgM (P=0.0014). The anti-CCP, which evaluated the qualitative results, was correct 99.1–100% of the time, with the exception being for the IG-18-02 specimen. The anti-CCP, which lacks international standards, requires patient-derived proficiency testing materials.

Keywords : Korean Association of External Quality Assessment Service, Complement, Immunoglobulins, Free light chain, Anti-cyclic citrullinated peptide
꽌 濡

쇅遺젙룄愿由ы봽濡쒓렇옩뿉 李몄뿬븯뒗 寃껋 寃궗쓽 떊猶곕룄瑜 뼢긽떆궗 닔 엳뒗 以묒슂븳 諛⑸쾿씠떎. 븳엫긽寃궗젙룄愿由ы삊쉶뿉꽌뒗 2016뀈遺꽣 깉濡쒖슫 슫쁺諛⑹떇쓽 李⑥꽭 떊鍮숇룄議곗궗궗뾽쓣 떆뻾븯怨 엳떎. 2018뀈뿉뒗 珥 6媛쒖쓽 遺꾨쪟媛 엳쑝硫, 吏꾨떒硫댁뿭븰 遺꾨쪟 븘옒뿉뒗 6媛쒖쓽 以묐텇瑜섎줈 援ъ꽦릺硫 삉 14 媛쒖쓽 꽭遺봽濡쒓렇옩쑝濡 굹돏떎. 吏꾨떒硫댁뿭븰 꽭遺봽濡쒓렇옩쓽 븯굹씤 蹂댁껜·硫댁뿭湲濡쒕텋由곌궗뒗 珥 9媛吏 寃궗쓽 떊鍮숇룄 議곗궗 빆紐⑹쓣 媛吏怨 엳떎. 蹂댁껜 쑀由ш꼍뇙, 硫댁뿭湲濡쒕텋由 諛 빆-cyclic citrullinated peptide (anti-CCP)媛 룷븿릺硫 씠뱾 寃궗뱾 媛곴컖 쟾떊꽦 솉諛섏꽦 猷⑦뫖뒪[1], 떎諛쒖꽦 怨⑥닔醫[2], 옄媛硫댁뿭꽦 媛꾩뿼[3], 瑜섎쭏떚뒪愿젅뿼[4]쓽 吏꾨떒湲곗뿉 룷븿릺뼱 엫긽쟻쑝濡 以묒슂븯떎.

씠뿉 옄뒗 2018뀈 븳엫긽寃궗젙룄愿由ы삊쉶쓽 떊鍮숇룄議곗궗궗뾽쑝濡 떎떆릺뿀뜕 蹂댁껜 · 硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩뿉 븳 떊鍮숇룄議곗궗궗뾽 寃곌낵瑜 遺꾩꽍븯뿬 蹂닿퀬븯怨좎옄 븳떎.

옱猷 諛 諛⑸쾿

1. 議곗궗빆紐

議곗궗빆紐⑹ complement C3, complement C4, free light chain κ, free light chain λ, immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin E (IgE), 빆-CCP寃궗쓽 9媛吏 빆紐⑹뿉 븳 떊鍮숇룄議곗궗瑜 떎떆븯떎.

2. 쇅遺떊鍮숇룄議곗궗 臾쇱쭏

蹂댁껜 · 硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩쓽 쇅遺떊鍮숇룄議곗궗뿉 씠슜맂 臾쇱쭏 븸긽쑝濡 맂 젙룄愿由щЪ吏덉씠뿀떎. Bio-Rad궗 (Bio-Rad Laboratories, Hercules, CA, USA)쓽 Liquichek Immunology Control쓣 궗슜븯떎. 4썡怨 10썡 뿰 2쉶뿉 嫄몄퀜 쉶李⑤퀎濡 3媛쒖쓽 젙룄愿由щЪ吏덉씠 깋룞蹂닿릺뼱 諛곗넚릺뿀쑝硫, 깋룞寃泥 닔졊 썑 媛뒫븳 鍮좊Ⅸ 떆媛 궡뿉 寃궗瑜 떆뻾븯룄濡 븞궡븯떎. 깋룞寃泥대 떎삩(18°C뿉꽌 25°C)뿉꽌 1떆媛 媛웾 諛⑹튂븯뿬 빐룞븯怨, 留묒 삁泥씠 븘땶 寃쎌슦 썝떖븳 썑뿉 留묒 삁泥쓣 궗슜븯룄濡 븯떎. 寃궗 떆뻾 썑 쉶떊 留덇컧씪 궡뿉 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽 솃럹씠吏 (http://eqas.keqas.org)뿉 寃곌낵瑜 엯젰븯룄濡 븞궡븯떎.

3. 寃곌낵 뙋젙 諛 遺꾩꽍

蹂댁껜 · 硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩쓽 媛곴컖 寃궗뿉 빐꽌 湲곌뿉꽌 엯젰븳 媛 寃궗빆紐⑹뿉 븳 젙蹂댁 寃곌낵瑜 湲 諛섏쑝濡 湲곌린쉶궗, 湲곌린뿉 뵲씪 넻怨꾨텇꽍쓣 떆뻾븯怨, 씠瑜 쟾泥 李몄뿬湲곌쓽 遺꾪룷瑜 蹂댁뿬二쇰뒗 怨듯넻蹂닿퀬꽌 媛쒕퀎湲곌쓽 룊媛寃곌낵瑜 蹂댁뿬二쇰뒗 湲곌蹂 蹂닿퀬꽌濡 굹늻뼱 蹂닿퀬븯떎. Complement C3, complement C4, free light chain κ, free light chain λ, IgA, IgG, IgM, IgE寃궗뒗 젙웾쟻 寃곌낵瑜, 빆-CCP寃궗뒗 젙꽦쟻 寃곌낵瑜 遺꾩꽍븯떎. 怨듯넻蹂닿퀬꽌뒗 3떒怨꾨줈 洹몃9솕븯뿬 넻怨꾩튂瑜 젣떆븯떎. 쟾泥 李몄뿬湲곌뿉 빐떦븯뒗 넻怨, 湲곌린쉶궗瑜 湲곗遺꾨쪟濡 븳 洹몃9쓽 넻怨꾩 媛 湲곌린瑜 꽭遺꾨쪟븳 洹몃9쓽 넻怨꾨 媛곴컖 젣떆븯떎.

젙웾寃궗 怨듯넻蹂닿퀬꽌뿉뒗 媛 洹몃9蹂 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂룞怨꾩닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪씠 룷븿릺룄濡 븯떎. 룊洹, 몴以렪李, 蹂룞怨꾩닔쓽 寃쎌슦 빐떦 遺꾨쪟蹂 遺꾩꽍뿉꽌 씠긽移섎 젣嫄고븳 썑 遺꾩꽍븳 媛믪쓣 젣떆븯떎. 씠긽移섎뒗 75띁꽱씪 媛(Q3)怨 25띁꽱씪 媛(Q1)쓽 李(Q3–Q1, interquartile range [IQR])쓽 1.5諛곕 珥덇낵븯뿬 Q1蹂대떎 궙嫄곕굹 Q3蹂대떎 넂 寃곌낵媛(<Q1-1.5×IQR 삉뒗 >Q3+1.5 ×IQR)쑝濡 젙쓽븯떎. 빐떦 遺꾨쪟뿉 냽븯뒗 湲곌 닔媛 10 媛 誘몃쭔씤 寃쎌슦뿉뒗 룊洹, 몴以렪李, 蹂룞怨꾩닔, 몴以렪李⑥닔 (standard deviation index, SDI)瑜 젣떆븯吏 븡怨, 湲곌 닔媛 3媛 誘몃쭔씤 寃쎌슦뿉뒗 以묒븰媛믩룄 젣떆븯吏 븡쑝硫, 湲곌 닔媛 1媛쒖씤 寃쎌슦뿉뒗 以묒븰媛믩쭔 蹂닿퀬븯떎. 젙웾寃궗 湲곌蹂 蹂닿퀬꽌뿉뒗 쟾泥닿린愿 諛 湲곗遺꾨쪟쓽 엳뒪넗洹몃옩怨 理쒕 12媛쒓퉴吏 늻쟻맂 SDI瑜 몴떆븯뒗 젅鍮-젣떇뒪 李⑦듃 諛 媛 湲곌쓽 寃곌낵뿉 빐 湲곗遺꾨쪟 諛 꽭遺꾨쪟濡 SDI瑜 젣怨듯븯떎. 빆-CCP 젙꽦寃궗 怨듯넻蹂닿퀬꽌뿉뒗 湲곌뿉꽌 蹂닿퀬븳 寃궗寃곌낵뱾씠 湲곗遺꾨쪟 諛 꽭遺꾨쪟蹂 넻怨꾨줈 援ъ꽦릺뿀떎. 젙꽦寃궗 湲곌蹂 蹂닿퀬꽌뿉뒗 寃궗寃곌낵, intended response 諛 룊媛寃곌낵媛 엳쑝硫, intended response뒗 떊猶고븷 留뚰븳 젙떟씠 뾾뒗 寃쎌슦뿉뒗 寃곌낵瑜 蹂닿퀬븳 湲곌뿉꽌 80% 씠긽쓽 씪移섎 蹂댁씠뒗 寃곌낵濡 븯떎.

넻怨꾩쟻 遺꾩꽍쓣 쐞빐꽌 넻怨꾪봽濡쒓렇옩 MedCalc Software ver. 16.8 (MedCalc Software, Mariakerke, Belgium)쓣 궗슜븯떎. 硫댁뿭湲濡쒕텋由 媛꾩쓽 蹂룞怨꾩닔 李⑥씠 쑀臾대뒗 Friedman test瑜 씠슜븯怨, complement C3 complement C4 洹몃━怨 free light chain κ free light chain λ 궗씠쓽 蹂룞怨 닔 李⑥씠뒗 Mann-Whitney test瑜 넻빐 援ы븯떎. P媛믪씠 0.05 씠븯씤 寃쎌슦 넻怨꾩쟻쑝濡 쑀쓽븯떎怨 媛꾩<븯떎.

寃곌낵 諛 怨좎같

2018뀈 蹂댁껜 · 硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩 떊鍮숇룄議곗궗뒗 媛 寃궗留덈떎 李몄뿬븯뒗 湲곌쓽 닔媛 떖옄쑝硫, free light chain쓽 李몄뿬湲곌 29媛쒖뿉꽌 빆-CCP 李몄뿬湲곌 115媛쒕줈 떎뼇븯떎. 媛 젙웾쟻 寃궗빆紐⑸퀎濡 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂룞怨꾩닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪쓽 遺꾪룷뒗 Table 1Table 2 媛숇떎. 蹂댁껜쓽 寃쎌슦 C3쓽 蹂룞怨꾩닔 以묒븰媛믪 4.9% C4쓽 蹂룞怨꾩닔 以묒븰媛믪 8.45%濡 C3쓽 蹂룞怨꾩닔媛 넻怨꾩쟻쑝濡 쑀쓽븯寃 궙븯떎(P=0.013) (Fig. 1). College of American Pathologists뿉꽌 二쇨븯뒗 떊鍮숇룄議곗궗궗뾽쓽 S-C 2016 봽濡쒓렇옩뿉꽌룄 C3 쓽 蹂룞怨꾩닔뒗 4.1%-5.1%쓽 踰붿쐞瑜 蹂댁吏留 C4쓽 蹂룞怨꾩닔뒗 6.7%-9.9% 踰붿쐞 궡뿉 엳뼱 援궡 쑀궗븯떎. 씠뒗 泥대궡뿉꽌 C3媛 뜑 넂 냽룄濡 議댁옱븯湲 븣臾몄뿉 궙 蹂룞怨꾩닔瑜 蹂댁씤 寃껋쑝濡 빐꽍맂떎.

Table 1 . Distribution of the complement and free light chain results in 2018.

Specimen no.No.Mean±standard deviationCoefficient of variation (%)MedianMinimumMaximum
Complement C3 (mg/dL)
 IG-18-018984.22±3.694.3984.87193
 IG-18-0289179.15±8.384.68179.7154197.8
 IG-18-038948.67±4.098.447.840.958
 IG-18-048876.66±3.774.977.067.284.0
 IG-18-0588178.21±8.744.9180.0158.0209.0
 IG-18-0688275.52±14.765.4279.0248.3337.0
 Median4.9
Complement C4 (mg/dL)
 IG-18-018914.67±1.026.9214.412.818
 IG-18-028932.81±2.828.58322839.5
 IG-18-038948.67±4.098.447.840.958
 IG-18-048813.47±1.178.713.011.816.7
 IG-18-058834.19±2.908.533.329.040.3
 IG-18-068853.53±4.328.152.544.062.5
 Median8.45
Free light chain, κ (mg/L)
 IG-18-013013.553±1.168.55813.3311.4222.71
 IG-18-023016.98±1.3798.1217.1214.1424.7
 IG-18-033020.268±1.9129.43620.4615.8528.14
 IG-18-042918.948±1.4827.819.0514.2521.84
 IG-18-052921.354±1.6457.721.3116.6425.01
 IG-18-062923.305±1.1715.023.4218.9028.16
 Median7.96
Free light chain, λ (mg/L)
 IG-18-013012.972±1.0377.99512.8810.0614.97
 IG-18-023016.227±1.2227.5316.3713.7118.89
 IG-18-033018.374±1.2546.82418.2115.9521.56
 IG-18-042914.754±0.7995.414.7513.1016.25
 IG-18-052917.611±0.8855.017.2916.3819.16
 IG-18-062919.545±1.0885.619.5118.0123.12
 Median6.21

Table 2 . Distribution of the immunoglobulin results in 2018.

Specimen no.No.Mean±standard deviationCoefficient of variation (%)MedianMinimumMaximum
Immunoglobulin A (mg/dL)
 IG-18-0180112.09±4.884.36112.8102121
 IG-18-0280232.2±10.764.64229.6215.8264
 IG-18-0380340.06±17.795.23337312.1395
 IG-18-0480112.88±5.845.2113.198.0124.0
 IG-18-0580239.38±8.213.4240.0221.0292.0
 IG-18-0680358.43±12.733.6361.3332.6457.5
 Median4.5
Immunoglobulin G (mg/dL)
 IG-18-0177740.37±36.844.98735634837
 IG-18-02771,261.29±49.753.941,264.21,155.41,570
 IG-18-03771,725.11±75.224.361,7101,5791,910
 IG-18-0477810.15±36.914.6807.6735.0931.0
 IG-18-05771,371.65±54.774.01,383.01,262.01,570.0
 IG-18-06771,912.82±94.464.91,919.01,751.02,190.0
 Median4.48
Immunoglobulin M (mg/dL)
 IG-18-017749.3452±3.15356.3907494257
 IG-18-0277108.7716±3.56543.2778110102129
 IG-18-0377159.409±5.47793.4364160.6147.7201
 IG-18-047751.24±2.565.051.045.060.0
 IG-18-0577120.53±4.433.7120.9109.0144.0
 IG-18-0677180.55±4.922.7181.0167.0233.0
 Median3.56
Immunoglobulin E (IU/mL)
 IG-18-017673.39±5.767.8573.750.187.7
 IG-18-0276156.02±11.797.56156.9114185.3
 IG-18-0376228.17±20.629.04231.6163270.8
 IG-18-047644.41±3.477.844.335.862.0
 IG-18-0576127.77±9.697.6127.396.7146.6
 IG-18-0676204.64±15.677.7203.7168.8237.0
 Median7.75

Figure 1.

Plot of the CV for complement C3 and complement C4 in 2018. The X-axis is the specimen number, which is displayed sequentially from IG-18-01 to IG-18-06. The dif- ference of immunoglobulin G CV was statistically significant between C3 and C4 using the Mann-Whitney test (P=0.013) for the analyses. Abbreviation: CV, coefficient of variation.


Free light chain κ free light chain λ쓽 蹂룞怨꾩닔쓽 以묒븰 媛믪 媛곴컖 7.96怨 6.21濡 free light chain κ쓽 蹂룞怨꾩닔媛 넂븯吏留 넻怨꾩쟻 李⑥씠뒗 뾾뿀떎(P=0.092) (Fig. 2). 떒겢濡좉컧留 蹂묒쬆 諛 삎吏덉꽭룷 愿젴 吏덊솚쓽 吏꾨떒湲곗뿉 룷븿릺뒗 以묒슂븳 寃궗씠吏留 援궡뿉꽌뒗 29媛 湲곌뿉꽌留 寃궗媛 떆뻾릺怨 엳뿀떎[2]. 쓽猷뚭린愿쓽 긽떦닔 寃궗媛 닔긽 쓽猶곕릺怨 엳쓣 寃껋쑝濡 異붿륫븷 닔 엳寃좊떎.

Figure 2.

Plot of the CV for free light chain κ and free light chain λ in 2018. The X-axis is the specimen number, which is dis- played sequentially from IG-18-01 to IG-18-06. The CV was not significantly different between free light chain κ and free light chain λ using the Mann-Whitney test for the analyses (P=0.092). Abbreviation: CV, coefficient of variation.


硫댁뿭湲濡쒕텋由곗 李몄뿬湲곌씠 씪젙븯吏 븡븯뒗뜲 IgA媛 80媛쒕줈 媛옣 留롮븯쑝硫, IgG 諛 IgM 77媛 湲곌, IgE 76媛 湲곌씠뿀떎. IgA, IgG, 諛 IgM쓽 蹂룞怨꾩닔뒗 以묒븰媛믪씠 4.5, 4.48, 3.56 쑝濡 뼇샇븯吏留, IgE쓽 蹂룞怨꾩닔 以묒븰媛믪 7.75濡 IgA, IgG, IgM쓽 蹂룞怨꾩닔뿉 鍮꾪빐 넻怨꾩쟻쑝濡 쑀쓽븯寃 넂븯떎 (P=0.0014) (Fig. 3). 씠뒗 IgE媛 泥대궡뿉 냼웾쑝濡 議댁옱븯硫, 痢≪젙湲곌린媛 BN II system (Siemens Healthcare Diagnostics Ltd., Erlangen, Germany)怨 媛숈 nephelometry遺꽣 Phadia 100 (Phadia AB, Uppsala, Sweden)怨 媛숈 fluorescent immunoassay源뚯 떎뼇븯湲 븣臾몄쑝濡 빐꽍맂떎.

Figure 3.

Plot of the CV for IgA, IgG, IgM, and IgE in 2018. The axis is the specimen number, which is displayed sequentially from IG-18-01 to IG-18-06. The CV of IgE was significantly different among immunoglobulin using the Friedman test (P=0.0014) for the analyses. Abbreviations: CV, coefficient of variation; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IgE, immunoglobulin E.


빆-CCP뒗 蹂댁껜·硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩 以 媛옣 李몄뿬 湲곌씠 留롮 寃궗濡, 1李 108媛 湲곌 2李 115媛 湲곌쑝濡 利앷븯떎. 젙꽦쟻 寃곌낵瑜 룊媛븯쑝硫 IG-18-02 寃泥대 젣쇅븯怨 99.1%-100%쓽 젙떟瑜좎쓣 蹂댁떎(Table 3). IG-18-02 寃泥대뒗 Roche궗(Mannheim, Germany)쓽 떆빟쓣 궗슜븯뒗 寃궗떎 紐⑤몢 쓬꽦쓣 蹂댁뿬 80% 씪移섏쑉뿉 룄떖븯吏 紐삵븯떎. 빆-CCP 떆빟 쁽옱 3꽭源뚯 굹 엳쑝硫, Roche궗쓽 떆빟 꽕紐낆꽌뿉뒗 긽뭹솕맂 2꽭 寃궗踰뺤뿉 빐꽌 몴以솕븯떎怨 湲곗닠릺뼱 엳떎. 빆-CCP뒗 쁽옱 援젣 몴以臾쇱쭏씠 뾾湲 븣臾몄뿉 떆빟 궡쓽 젙룄愿由щЪ吏덇낵 calibrator媛 엫쓽濡 젙빐吏 떒쐞濡쒖뜥 젣怨듬릺怨 엳떎. 洹몃옒꽌 꽌濡 떎瑜 떆빟 媛꾩쓽 젙웾쟻 寃곌낵뒗 긽샇 鍮꾧탳븷 닔 뾾쑝硫, 궎듃 媛꾩쓽 뼇꽦 cut-off룄 留ㅼ슦 꼻 踰붿쐞뿉 嫄몄퀜 엳떎. 씠윭븳 臾몄젣젏뱾쓣 빐寃고븯湲 쐞빐꽌 2017뀈 10썡뿉 媛쒖턀맂 꽭怨꾨낫嫄닿린援(World Health Organization)쓽 biological standardization 쟾臾멸 쐞썝쉶뿉꽌 1李 빆-CCP 援젣몴以臾쇱쭏쓣 젣議고븯湲곕줈 寃곗젙븯떎[5]. IG-18-02 寃泥댁쓽 궙 씪移섏쑉 援젣몴以臾쇱쭏씠 뾾뒗 긽솴뿉꽌 젙룄愿由щЪ吏덉쓣 씠슜븯뿬 떊鍮숇룄議곗궗瑜 븯湲 븣臾몄뿉 諛쒖깮븳 臾몄젣씪怨 븷 닔 엳떎. 씠瑜 媛쒖꽑븯湲 쐞빐꽌뒗 솚옄 寃泥 쑀옒쓽 떊鍮숇룄 議곗궗 臾쇱쭏쓣 젣옉 媛쒕컻븷 븘슂꽦씠 엳떎. 솚옄 寃泥 쑀옒 떊鍮숇룄議곗궗 臾쇱쭏 matrix 슚怨쇨 뾾뼱꽌 떎젣 寃궗떎쓽 젙룄愿由 닔뻾뒫젰쓣 옒 룊媛븷 닔 엳쓣 寃껋쑝濡 깮媛곷맂떎.

Table 3 . The proficiency testing results for anti-cyclic citrullinated peptide in 2018.

Specimen no.No.ResultIntended

NegativePositive
IG-18-01108108 (100.0)-Negative
IG-18-0210843 (39.8)*65 (60.2)Less than 80% consensus
IG-18-031081 (0.9)107 (99.1)Positive
IG-18-04115115 (100.0)-Negative
IG-18-051151 (0.9)114 (99.1)Positive
IG-18-06115-115 (100.0)Positive

Values are presented as a number (%)..

*All 41 laboratories that used reagent of Roche (Mannheim, Germany) reported a negative result.0


2018뀈 蹂댁껜 · 硫댁뿭湲濡쒕텋由곌궗 봽濡쒓렇옩 떊鍮숇룄議곗궗뒗 쟾諛섏쟻쑝濡 뼇샇븳 蹂룞怨꾩닔瑜 蹂댁뿬 二쇱뿀떎. 젙꽦쟻 룊媛瑜 븳 빆-CCP 빆紐⑹ 솚옄 寃泥 쑀옒 떊鍮숇룄議곗궗 臾쇱쭏쓽 븘슂꽦쓣 젣湲고븯떎. 蹂 봽濡쒓렇옩쓽 寃궗빆紐⑸뱾 떎뼇븳 吏덊솚쓽 吏꾨떒 湲곗뿉 룷븿릺뼱 엳湲 븣臾몄뿉 吏냽쟻씤 李몄뿬媛 븘닔쟻씠떎. 씠瑜 넻븳 寃궗떎쓽 吏 뼢긽씠 솚옄쓽 吏꾨즺쁺뿭뿉 겙 룄씠 릺뿀쓣 寃껋씠떎.

References
  1. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400-12.
    Pubmed CrossRef
  2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
    Pubmed CrossRef
  3. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76.
    Pubmed CrossRef
  4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
    Pubmed CrossRef
  5. Expert Committee on Biological Standardization, World Health Organization. Requests to initiate new WHO reference material project for blood products and IVDs. Geneva: World Health Organization, 2017.